CASPS

Phase II trial of cediranib in the treatment of patients with alveolar soft part sarcoma.

Disease site: Other cancer Sarcoma

Treatment Modality: Systemic therapy

Status: In follow-up

Trial details

CASPS is a two-arm, randomised, double blind, international, multicentre phase II trial to confirm the ability of the anti-angiogenic drug cediranib to halt disease progression in patients with metastatic alveolar soft part sarcoma.

Thirty-six patients will be recruited from 12 sites in the UK, Australia and Spain over a five-year period. Patients will receive either cediranib or placebo until 24 weeks post-randomisation, when treatment will be unblinded and all patients on placebo and those who have not progressed on active treatment will begin or continue taking cediranib. Treatment will continue until objective disease progression and participants will be followed up for life.

Further information

Chief Investigator: Professor Ian Judson, The Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead: Professor Judith Bliss

Trial management contact: [email protected] 

ISRCTN: 63733470

Sponsor: The Institute of Cancer Research

Funding: Cancer Research UK (CRUK/10/021), AstraZenenca

View CASPS on the National Institute for Health Research website: NIHR - Be Part Of Research

Patient friendly information is available from the following link:

CancerHelp UK 

Publications and presentations

Judson I, Snowdon C, Fox L, Kernaghan S, Morden J, Bliss J; on behalf of the CASPS Trial Management Group. Trial in progress: a phase II, international trial of cediranib in the treatment of patients with alveolar soft part sarcoma (CASPS) C2130/A12118. Presented at: 10th National Cancer Research Institute Cancer Conference; 2014 Nov 2-5; Liverpool, UK.

Judson I, Snowdon C, Fox L, Kernaghan S, Morden J, Bliss J; on behalf of the CASPS Trial Management Group. Trial in progress: a phase II international trial of cediranib in the treatment of patients with alveolar soft part sarcoma (CASPS) C2130/A12118. Presented at: British Sarcoma Group Conference; 2014 Feb 26-28; Nottingham, UK.

Judson I, Olmos D, Snowdon C, Fox L, Kernaghan S, Morden J, Bliss J; on behalf of the CASPS Trial Management Group. Trial in progress: a phase II international trial of cediranib in the treatment of patients with aveolar soft part sarcoma (CASPS) CRUK ref: C2130/A12118. Presented at: British Sarcoma Group Conference; 2012 Feb 29-Mar 2; Oxford, UK.

Judson I, Morden J P, Kilburn L, Leahy M, Benson C, Bhadri V, Campbell-Hewson Q, Cubedo R, Dangoor A, Fox L, Hennig I, Jarman K, Joubert W, Kernaghan S, Pousa A L, McNeil C, Seddon B, Snowdon C, Tattersall M, Toms C, Trufero J M, Bliss J M - Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial

breast cancer cell
Major trial shows prolonged benefit of olaparib in early-stage inherited breast cancer

12/12/24

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major clinical trial show.
See full story
Breast cancer cell spheroid blue and purple
New understanding of aggressive form of breast cancer paves the way for tests and treatments

10/12/24

Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to treatment, and when it will return.
See full story